-
Loading metrics
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- Manish A. Shah,
- Zev A. Wainberg,
- Daniel V. T. Catenacci,
- Howard S. Hochster,
- James Ford,
- Pamela Kunz,
- Fa-Chyi Lee,
- Howard Kallender,
- Fabiola Cecchi,
- Daniel C. Rabe
x
- Published: March 14, 2013
- https://doi.org/10.1371/journal.pone.0054014
Viewed
Cited
Discussed
Powered by Altmetric
Questions or concerns about usage data? Please let us know.
Saved